Premium
Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus
Author(s) -
Cheung N Wah,
Conn Jennifer J,
D’Emden Michael C,
Gunton Jenny E,
Jenkins Alicia J,
Ross Glynis P,
Sinha Ashim K,
Andrikopoulos Sofianos,
Colagiuri Stephen,
Twigg Stephen M
Publication year - 2009
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.2009.tb02819.x
Subject(s) - medicine , position statement , diabetes mellitus , glycated haemoglobin , type 2 diabetes , disease , glycated hemoglobin , blood pressure , pregnancy , type 2 diabetes mellitus , diabetes management , intensive care medicine , pediatrics , endocrinology , family medicine , biology , genetics
Tight glycaemic control reduces the risk of development and progression of organ complications in people with type 1 or type 2 diabetes. In this position statement, the Australian Diabetes Society recommends a general target glycated haemoglobin (HbA 1c ) level of ≤ 7.0% for most patients. This position statement also provides guidelines for the individualisation of glycaemic targets to a tighter or lesser degree, with a recommended target HbA 1c level of ≤ 6.0% in some people, or up to ≤ 8.0% in others. Individualisation of the HbA 1c target is based on patient‐specific factors, such as the type of diabetes and its duration, pregnancy, diabetes medication being taken, presence of cardiovascular disease, risk of and problems from hypoglycaemia, and comorbidities. Management of diabetes also includes: adequate control of other cardiovascular risk factors, including weight, blood pressure and lipid serum levels; antiplatelet therapy; and smoking cessation.